Recap: Four Auto-Injectors on the Horizon

As recent events plainly indicate, consumers are painfully aware of the lack of competition and choice in the marketplace for epinephrine auto-injectors, the only drug indicated when life-threatening anaphylaxis strikes.

The problem was further exacerbated when Sanofi recalled their popular Auvi-Q device and announced an exit from the market in February. Since then, we have been reporting on alternatives making their way through the development and FDA approval process.

Click to visit sponsor

If you are interested in keeping abreast of the latest in auto-injector alternatives, keep your eye on our blog or subscribe to our Newsletter for periodic updates:

Subscribe for 2-3 email updates per month and never miss an advisory! Unsubscribe at any time. We pledge never to share your address.

Here are articles we published in the past year on four noteworthy auto-injector designs currently at various stages in the pipeline with more to come:

Epinephrine Auto-injectors: Where is the Long Promised Generic?

Delivering the Next Generation Auto-Injector

Patent Issued for Innovative Auto-Injector Mechanism

Medical Device Company Tests Compact Auto-Injector Design

Adamis Auto-Injector Rejected by FDA

Note of disclosure: Mylan is an advertiser with SnackSafely.com.
Print or share this article
Click to visit sponsor

LEAVE A REPLY